Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E M Jaffee

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1996
Enhanced immune priming with spatial distribution of paracrine cytokine vaccinesE M Jaffee, M C Thomas, A Y Huang, et al.
Cytotherapy|July 26, 2005
Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facilityJ M Davis-Sproul, M P Harris, N E Davidson, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1996
Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumorsR C Thompson, D M Pardoll, E M Jaffee, et al.
Cancer Research|May 15, 1993
High efficiency gene transfer into primary human tumor explants without cell selectionE M Jaffee, G Dranoff, L K Cohen, et al.
Cancer Research|February 28, 2001
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumorsR T Reilly, J P Machiels, L A Emens, et al.
Cancer Research|April 28, 2001
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized miceJ P Machiels, R T Reilly, L A Emens, et al.
Immunity|November 9, 2000
Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complexJ E Slansky, F M Rattis, L F Boyd, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 1998
Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patientsT F Greten, J E Slansky, R Kubota, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1995
Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trialsE M Jaffee, A Lazenby, J Meurer, et al.
Cancer Research|June 1, 1995
Consistent chromosome abnormalities in adenocarcinoma of the pancreasC A Griffin, R H Hruban, L A Morsberger, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1996
Enhanced immune priming with spatial distribution of paracrine cytokine vaccinesE M Jaffee, M C Thomas, A Y Huang, et al.
Cytotherapy|July 26, 2005
Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facilityJ M Davis-Sproul, M P Harris, N E Davidson, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1996
Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumorsR C Thompson, D M Pardoll, E M Jaffee, et al.
Cancer Research|May 15, 1993
High efficiency gene transfer into primary human tumor explants without cell selectionE M Jaffee, G Dranoff, L K Cohen, et al.
Cancer Research|February 28, 2001
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumorsR T Reilly, J P Machiels, L A Emens, et al.
Cancer Research|April 28, 2001
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized miceJ P Machiels, R T Reilly, L A Emens, et al.
Immunity|November 9, 2000
Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complexJ E Slansky, F M Rattis, L F Boyd, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 1998
Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patientsT F Greten, J E Slansky, R Kubota, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1995
Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trialsE M Jaffee, A Lazenby, J Meurer, et al.
Cancer Research|June 1, 1995
Consistent chromosome abnormalities in adenocarcinoma of the pancreasC A Griffin, R H Hruban, L A Morsberger, et al.
Pageof 5